Piper Sandler analyst Yasmeen Rahimi downgraded Prometheus (RXDX) to Neutral from Overweight with a price target of $200, up from $138, after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX: